Neural Regeneration Research ›› 2022, Vol. 17 ›› Issue (9): 1861-1866.doi: 10.4103/1673-5374.335690

    Next Articles

Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity

Juan Segura-Aguilar1, *, Bengt Mannervik2, José Inzunza3, Mukesh Varshney3, Ivan Nalvarte3, Patricia Muñoz1, 4   

  1. 1Molecular and Clinical Pharmacology ICBM Faculty of Medicine University of Chile, Santiago, Chile; 2Department of Biochemistry and Biophysics, Arrhenius Laboratories, Stockholm University, Stockholm, Sweden; 3Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; 4Nucleo de Química y Bioquímica, Facultad de Estudios Interdisciplinarios, Universidad Mayor, Santiago, Chile
  • Online:2022-09-15 Published:2022-03-03
  • Contact: Juan Segura-Aguilar, PhD, jsegura@med.uchile.cl.
  • Supported by:
    This work was supported by ANID-FONDECYT 1170033 (to JSA), ANID-STINT-CONICYT CS2018-7940 (to JSA, IN, JI, MV), Swedish Research Council grant 2015-04222 to BM.

Abstract: Astrocytes protect neurons by modulating neuronal function and survival. Astrocytes support neurons in several ways. They provide energy through the astrocyte-neuron lactate shuttle, protect neurons from excitotoxicity, and internalize neuronal lipid droplets to degrade fatty acids for neuronal metabolic and synaptic support, as well as by their high capacity for glutamate uptake and the conversion of glutamate to glutamine. A recent reported astrocyte system for protection of dopamine neurons against the neurotoxic products of dopamine, such as aminochrome and other o-quinones, were generated under neuromelanin synthesis by oxidizing dopamine catechol structure. Astrocytes secrete glutathione transferase M2-2 through exosomes that transport this enzyme into dopaminergic neurons to protect these neurons against aminochrome neurotoxicity. The role of this new astrocyte protective mechanism in Parkinson´s disease is discussed.

Key words: aminochrome, astrocytes, dopamine, dopaminergic neurons, exosomes, glutathione transferase M2-2, neuroprotection, Parkinson’s disease